OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer - Concepedia

Concepedia

Publication | Open Access

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

DOI Full Paper Access

725

Citations

6

References

2019

Year

Mark E. Robson, Nadine Tung, Pierfranco Conté, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong,

Annals of Oncology

References

	Year	Citations

Page 1